propranolol has been researched along with Skin Ulcer in 20 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Skin Ulcer: An ULCER of the skin and underlying tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propranolol is a valuable therapeutic alternative for treatment of ulcerated haemangiomas and effectively reduces pain." | 9.22 | Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. ( Gangopadhyay, AN; Gupta, DK; Pandey, V; Sharma, SP; Tiwari, P, 2016) |
| "A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication." | 7.78 | Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding? ( Buffon, RB; Cavalli, R; Colli, AM; de Souza, M; Gelmetti, C, 2012) |
| "Propranolol was given to 20 patients with IH, who suffered from ulceration at the start of treatment (mean age at onset of treatment, 3." | 5.37 | Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. ( Hermans, DJ; Schultze Kool, LJ; van Beynum, IM; van de Kerkhof, PC; van der Vleuten, CJ; Wijnen, MH, 2011) |
| "Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH." | 5.37 | Propranolol for treatment of ulcerated infantile hemangiomas. ( Barbarot, S; Bodak, N; Hadj-Rabia, S; Hamel-Teillac, D; Kupfer-Bessaguet, I; Lacour, JP; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Naouri, M; Nguyen, JM; Saint-Jean, M; Stalder, JF; Vabres, P, 2011) |
| "Hemangioma is the most common tumor of infancy." | 5.35 | [Response to oral propranolol therapy for ulcerated hemangiomas in infancy]. ( Michel, JL; Patural, H, 2009) |
| "Propranolol is a valuable therapeutic alternative for treatment of ulcerated haemangiomas and effectively reduces pain." | 5.22 | Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. ( Gangopadhyay, AN; Gupta, DK; Pandey, V; Sharma, SP; Tiwari, P, 2016) |
| "A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication." | 3.78 | Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding? ( Buffon, RB; Cavalli, R; Colli, AM; de Souza, M; Gelmetti, C, 2012) |
| "Infantile hemangioma is the most common vascular tumor of childhood." | 2.49 | [What's new about infantile hemangiomas?]. ( Dreyfus, I; Maza, A; Mazereeuw-Hautier, J, 2013) |
| "Infantile hemangiomas are the most common vascular tumors in childhood." | 1.56 | Evaluation of Clinical Properties and Treatment Responses of Infantile Hemangioma. ( Azizoglu, M; Corapcioglu, F; Demirsoy, U; Yildirimcakar, D, 2020) |
| "Oral propranolol is now the treatment of choice in many situations." | 1.39 | Ulcerated nasal infantile haemangioma treated by oral propranolol. ( Al Dosari, S; Riad, H, 2013) |
| "Propranolol was given to 20 patients with IH, who suffered from ulceration at the start of treatment (mean age at onset of treatment, 3." | 1.37 | Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. ( Hermans, DJ; Schultze Kool, LJ; van Beynum, IM; van de Kerkhof, PC; van der Vleuten, CJ; Wijnen, MH, 2011) |
| "Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH." | 1.37 | Propranolol for treatment of ulcerated infantile hemangiomas. ( Barbarot, S; Bodak, N; Hadj-Rabia, S; Hamel-Teillac, D; Kupfer-Bessaguet, I; Lacour, JP; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Naouri, M; Nguyen, JM; Saint-Jean, M; Stalder, JF; Vabres, P, 2011) |
| " A dosage of 2 mg/kg/d, is usually employed with a dosing interval of 8 hours." | 1.37 | [Propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations]. ( López-Gutiérrez, JC; Ruiz-Rodriguez, R; Sánchez-Carpintero, I, 2011) |
| "Hemangioma is the most common tumor of infancy." | 1.35 | [Response to oral propranolol therapy for ulcerated hemangiomas in infancy]. ( Michel, JL; Patural, H, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tirelli, LL | 1 |
| Luna, PC | 1 |
| Panizzardi, AA | 1 |
| Larralde, M | 1 |
| Yildirimcakar, D | 1 |
| Demirsoy, U | 1 |
| Azizoglu, M | 1 |
| Corapcioglu, F | 1 |
| Ji, Y | 1 |
| Yang, K | 1 |
| Zhou, J | 1 |
| Zhang, X | 1 |
| Xiang, B | 1 |
| Jiang, X | 1 |
| Xu, X | 1 |
| Qiu, T | 1 |
| Dai, S | 1 |
| Kong, F | 1 |
| Lu, G | 1 |
| Qiu, Q | 1 |
| Zhang, Y | 1 |
| Chen, S | 1 |
| Babic, V | 1 |
| Schoeffler, A | 1 |
| Moawad, S | 1 |
| Mainard, L | 1 |
| Schmutz, JL | 1 |
| Bursztejn, AC | 1 |
| Dreyfus, I | 1 |
| Maza, A | 1 |
| Mazereeuw-Hautier, J | 2 |
| Luu, M | 1 |
| Frieden, IJ | 1 |
| Al Dosari, S | 1 |
| Riad, H | 1 |
| Tiwari, P | 1 |
| Pandey, V | 1 |
| Gangopadhyay, AN | 1 |
| Sharma, SP | 1 |
| Gupta, DK | 1 |
| Lie, E | 1 |
| Püttgen, KB | 1 |
| Cheng, CE | 1 |
| Friedlander, SF | 1 |
| Léauté-Labrèze, C | 2 |
| Harper, JI | 1 |
| Hoeger, PH | 1 |
| Yu, X | 1 |
| Zhang, J | 1 |
| Wu, Z | 1 |
| Liu, M | 1 |
| Chen, R | 1 |
| Gu, Y | 1 |
| Li, M | 1 |
| Yao, Z | 1 |
| Michel, JL | 1 |
| Patural, H | 1 |
| Hermans, DJ | 1 |
| van Beynum, IM | 1 |
| Schultze Kool, LJ | 1 |
| van de Kerkhof, PC | 1 |
| Wijnen, MH | 1 |
| van der Vleuten, CJ | 1 |
| Saint-Jean, M | 1 |
| Bodak, N | 1 |
| Hamel-Teillac, D | 1 |
| Kupfer-Bessaguet, I | 1 |
| Lacour, JP | 1 |
| Naouri, M | 1 |
| Vabres, P | 1 |
| Hadj-Rabia, S | 1 |
| Nguyen, JM | 1 |
| Stalder, JF | 1 |
| Barbarot, S | 1 |
| Kim, LHC | 1 |
| Hogeling, M | 1 |
| Wargon, O | 1 |
| Jiwane, A | 1 |
| Adams, S | 1 |
| Sánchez-Carpintero, I | 1 |
| Ruiz-Rodriguez, R | 1 |
| López-Gutiérrez, JC | 1 |
| Cavalli, R | 1 |
| Buffon, RB | 1 |
| de Souza, M | 1 |
| Colli, AM | 1 |
| Gelmetti, C | 1 |
| Armour, K | 1 |
| Lowe, P | 1 |
| Hoffbrand, BI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "'' Efficacy of Propranolol in the Treatment of Infantile Hemangioma"[NCT04684667] | Phase 2 | 100 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | ||
| A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma[NCT01072045] | Phase 2 | 50 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for propranolol and Skin Ulcer
| Article | Year |
|---|---|
[Rare presentations of infantile hemangiomas: 4 cases].
Topics: Biopsy; Buttocks; Delayed Diagnosis; Erythema; Facial Neoplasms; Female; Foot Diseases; Hemangioma, | 2018 |
[What's new about infantile hemangiomas?].
Topics: Hemangioma; Humans; Infant, Newborn; Propranolol; Skin Neoplasms; Skin Ulcer; Vasodilator Agents | 2013 |
Haemangioma: clinical course, complications and management.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Cicatrix; Congenita | 2013 |
Infantile hemangiomas, complications and treatments.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Airway Obstruction; Drug Therapy, Combination; | 2016 |
Infantile haemangioma.
Topics: Adrenergic beta-Antagonists; Heart Failure; Hemangioma; Humans; Infant; Propranolol; Respiratory Dis | 2017 |
LUMBAR syndrome: A case manifesting as cutaneous infantile hemangiomas of the lower extremity, perineum and gluteal region, and a review of published work.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Biopsy; Buttocks; Female; Hemangioma; Humans; | 2017 |
1 trial available for propranolol and Skin Ulcer
| Article | Year |
|---|---|
Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study.
Topics: Acetaminophen; Administration, Oral; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Hem | 2016 |
13 other studies available for propranolol and Skin Ulcer
| Article | Year |
|---|---|
[Management of ulcers on a segmental hemangioma: A combination of systemic and topical therapies in two pediatric cases].
Topics: Administration, Oral; Child; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Skin Ulcer; Tr | 2022 |
Evaluation of Clinical Properties and Treatment Responses of Infantile Hemangioma.
Topics: Age Factors; Esthetics; Facial Neoplasms; Female; Glucocorticoids; Hemangioma; Hemorrhage; Humans; I | 2020 |
Propranolol for the treatment of ulcerated infantile hemangiomas: A prospective study.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Prospec | 2022 |
Ulcerated nasal infantile haemangioma treated by oral propranolol.
Topics: Administration, Oral; Drug Administration Schedule; Female; Hemangioma, Capillary; Humans; Infant; N | 2013 |
Corticosteroids as an adjunct to propranolol for infantile haemangiomas complicated by recalcitrant ulceration.
Topics: Administration, Oral; Chronic Disease; Drug Therapy, Combination; Glucocorticoids; Hemangioma; Human | 2017 |
[Response to oral propranolol therapy for ulcerated hemangiomas in infancy].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Forearm; Hemangioma; Humans; Infant; Prop | 2009 |
Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls.
Topics: Adrenergic beta-Antagonists; Female; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Male; Prop | 2011 |
Propranolol for treatment of ulcerated infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Female; Head and Neck Neoplasms; Hemangioma; H | 2011 |
Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2011 |
[Propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Bradycardia; Bronchial Spasm; Clinical Trials | 2011 |
Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding?
Topics: Antineoplastic Agents; Female; Hemangioma, Capillary; Humans; Hyperkalemia; Hyperphosphatemia; Infan | 2012 |
Complicated lichenoid drug eruption.
Topics: Antiviral Agents; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hepatitis C; Hum | 2005 |
Peripheral skin necrosis complicating beta-blockade.
Topics: Aged; Female; Humans; Male; Middle Aged; Necrosis; Propranolol; Skin; Skin Ulcer; Toes | 1979 |